AnGes has been granted a patent for RNA molecules targeting specific sequences to inactivate mutant BEST1 alleles. The method involves delivering RNA molecules and CRISPR nuclease to cells containing mutant and functional BEST1 alleles. GlobalData’s report on AnGes gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AnGes, NSAID cancer drugs was a key innovation area identified from patents. AnGes's grant share as of January 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11827879B2) discloses a method for inactivating a mutant Bestrophin 1 (BEST1) allele in a cell containing both a mutant BEST1 allele and a functional BEST1 allele. The method involves delivering a composition comprising specific RNA molecules and an RNA guided CRISPR nuclease. The first RNA molecule targets a specific single nucleotide polymorphism (SNP) position in the mutant BEST1 allele, while the second RNA molecule targets a sequence present in an intron of both the mutant and functional alleles.
Furthermore, the method includes the use of guide RNA molecules with sequences that bind to a CRISPR nuclease, linker portions in the RNA molecules, and tracrRNA sequences. The inactivation process results in the production of a truncated protein from the mutated allele and a functional protein from the functional allele. The RNA guided CRISPR nuclease utilized in the method requires a specific protospacer adjacent motif (PAM) and can be either a Streptococcus pyogenes Cas9 nuclease or a Staphylococcus aureus Cas9 nuclease. Specific sequences for the guide RNA molecules are also provided in the claims, offering a detailed framework for implementing the method effectively.
To know more about GlobalData’s detailed insights on AnGes, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
